scri-carb7h3
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2019 (NCT04185038)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Central Nervous System Neoplasms · Phase 1
- Choroid Plexus Neoplasms · Phase 1
- Diffuse Intrinsic Pontine Glioma · Phase 1
- Ependymoma · Phase 1
- Glioma · Phase 1
- Medulloblastoma · Phase 1
- Neoplasms · Phase 1
- Neoplasms, Germ Cell and Embryonal · Phase 1
- Neuroectodermal Tumors, Primitive · Phase 1
- Rhabdoid Tumor · Phase 1
Mechanism of action
- CD276 antigenImmunity, passive
CD276 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04185038 | Phase 1 | Dec 31, 2019 | University of Washington |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2019 |
1 organizations
Page 1 / 1